peoplePerson
Michael von Bergwelt
Michael von Bergwelt is a haematologist who leads LMU's cell therapy and immuno-oncology programme.
Michael von Bergwelt directs haematology and oncology at LMU Munich, with research on CAR-T therapy, bispecifics, and the management of immune-related toxicities.
Role
Director, Department of Medicine III (Hematology and Oncology), LMU Munich
Institution
Specialisms
HaematologyCell therapyImmunotherapy toxicity
Profiles
Pages like this
not linked directly; found by shared links- TermHypogammaglobulinaemia and infection risk after B-cell therapies
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific), CAR-T cell therapy.
- ProductPasritamig
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific).
- IdeaHead-to-head bispecific vs CAR-T in second-line LBCL
- ProductBrexucabtagene autoleucel
- TrialELIANA
- TermCytokine
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific), CAR-T cell therapy.
- InstitutionComprehensive Cancer Center Mainfranken, University Hospital Würzburg
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific), CAR-T cell therapy.
- TrialGD2-CART01 (Bambino Gesù phase 1/2)